 Brian Greffe
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Ewing | 3 | 2025 | 87 | 0.460 |
Why?
| | Kidney Neoplasms | 4 | 2021 | 347 | 0.400 |
Why?
| | Hepatoblastoma | 4 | 2022 | 42 | 0.390 |
Why?
| | Liver Neoplasms | 4 | 2022 | 636 | 0.280 |
Why?
| | Cisplatin | 3 | 2025 | 299 | 0.280 |
Why?
| | Bone Neoplasms | 2 | 2025 | 229 | 0.260 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 102 | 0.240 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 58 | 0.230 |
Why?
| | Rhabdomyosarcoma | 2 | 2019 | 64 | 0.230 |
Why?
| | Clonal Evolution | 1 | 2025 | 39 | 0.230 |
Why?
| | Wilms Tumor | 2 | 2018 | 78 | 0.220 |
Why?
| | Granuloma, Plasma Cell | 1 | 2003 | 13 | 0.210 |
Why?
| | Dexamethasone | 1 | 2025 | 352 | 0.200 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 274 | 0.200 |
Why?
| | Neoplasms | 4 | 2025 | 2454 | 0.190 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2044 | 0.190 |
Why?
| | Hearing Loss | 1 | 2025 | 209 | 0.190 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.180 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 82 | 0.180 |
Why?
| | Eye Neoplasms | 1 | 2021 | 16 | 0.180 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 28 | 0.180 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1161 | 0.180 |
Why?
| | Ribonuclease III | 1 | 2021 | 37 | 0.170 |
Why?
| | Child | 25 | 2025 | 20882 | 0.170 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 66 | 0.170 |
Why?
| | Adolescent | 25 | 2025 | 20415 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 270 | 0.160 |
Why?
| | Protein C | 2 | 1989 | 47 | 0.160 |
Why?
| | Child, Preschool | 16 | 2025 | 10487 | 0.160 |
Why?
| | Hodgkin Disease | 2 | 2016 | 133 | 0.150 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 70 | 0.150 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 417 | 0.140 |
Why?
| | Survivors | 5 | 2016 | 462 | 0.140 |
Why?
| | Lung Diseases | 1 | 2003 | 741 | 0.130 |
Why?
| | Cytodiagnosis | 1 | 2017 | 32 | 0.130 |
Why?
| | Frozen Sections | 1 | 2017 | 26 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 18 | 0.130 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 149 | 0.130 |
Why?
| | Head and Neck Neoplasms | 2 | 2021 | 544 | 0.130 |
Why?
| | Nuclear Proteins | 1 | 2021 | 660 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 627 | 0.120 |
Why?
| | Health Planning | 1 | 2015 | 46 | 0.120 |
Why?
| | Male | 29 | 2025 | 63691 | 0.120 |
Why?
| | Prognosis | 5 | 2025 | 3772 | 0.120 |
Why?
| | Osteosarcoma | 2 | 2007 | 70 | 0.110 |
Why?
| | Abdomen, Acute | 1 | 1994 | 18 | 0.110 |
Why?
| | Infant | 13 | 2025 | 8987 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2022 | 833 | 0.110 |
Why?
| | Transition to Adult Care | 1 | 2015 | 82 | 0.110 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 228 | 0.100 |
Why?
| | Survival Rate | 5 | 2019 | 1872 | 0.100 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 19 | 0.100 |
Why?
| | Heart Diseases | 2 | 2016 | 352 | 0.100 |
Why?
| | Humans | 39 | 2025 | 129687 | 0.100 |
Why?
| | Sarcoma | 1 | 2015 | 175 | 0.100 |
Why?
| | Female | 27 | 2025 | 68751 | 0.100 |
Why?
| | Gene Rearrangement | 1 | 2013 | 148 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 129 | 0.100 |
Why?
| | Bone Marrow Transplantation | 3 | 2008 | 277 | 0.090 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.090 |
Why?
| | Embolectomy | 1 | 2011 | 13 | 0.090 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 231 | 0.090 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2343 | 0.090 |
Why?
| | Tumor Lysis Syndrome | 1 | 2010 | 8 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2010 | 1560 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 3705 | 0.080 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 103 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 212 | 0.080 |
Why?
| | Risk Assessment | 3 | 2015 | 3260 | 0.080 |
Why?
| | Brain Neoplasms | 4 | 1999 | 1149 | 0.070 |
Why?
| | Retrospective Studies | 9 | 2022 | 14525 | 0.070 |
Why?
| | SEER Program | 3 | 2016 | 202 | 0.070 |
Why?
| | Young Adult | 6 | 2025 | 12457 | 0.070 |
Why?
| | Leiomyosarcoma | 2 | 1998 | 26 | 0.070 |
Why?
| | Receptors, Erythropoietin | 1 | 2007 | 20 | 0.070 |
Why?
| | Translocation, Genetic | 2 | 2021 | 92 | 0.070 |
Why?
| | Topotecan | 1 | 2007 | 12 | 0.070 |
Why?
| | Fetal Blood | 1 | 1989 | 318 | 0.070 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2007 | 67 | 0.070 |
Why?
| | Survival Analysis | 3 | 2018 | 1270 | 0.070 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2006 | 12 | 0.070 |
Why?
| | Carboplatin | 1 | 2006 | 139 | 0.060 |
Why?
| | Neuroblastoma | 2 | 2006 | 151 | 0.060 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 201 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 229 | 0.060 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2006 | 71 | 0.060 |
Why?
| | Adult | 14 | 2019 | 35607 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 3153 | 0.060 |
Why?
| | Injection, Intratympanic | 1 | 2025 | 1 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2025 | 4892 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1097 | 0.060 |
Why?
| | Primary Health Care | 1 | 2015 | 1687 | 0.060 |
Why?
| | Gels | 1 | 2025 | 83 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 426 | 0.060 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 70 | 0.060 |
Why?
| | Neoplasms, Second Primary | 1 | 2006 | 106 | 0.060 |
Why?
| | Immunologic Factors | 1 | 2006 | 229 | 0.060 |
Why?
| | Databases, Factual | 3 | 2018 | 1269 | 0.050 |
Why?
| | Disease-Free Survival | 2 | 2019 | 646 | 0.050 |
Why?
| | Incidence | 3 | 2007 | 2644 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 578 | 0.050 |
Why?
| | Abdominal Abscess | 1 | 2003 | 26 | 0.050 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2003 | 12 | 0.050 |
Why?
| | Spinal Neoplasms | 1 | 2003 | 29 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2021 | 1201 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 426 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 610 | 0.050 |
Why?
| | Recurrence | 2 | 2003 | 1012 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2006 | 1368 | 0.050 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 24 | 0.050 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 24 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2025 | 869 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 627 | 0.040 |
Why?
| | Infant, Newborn | 4 | 2016 | 5759 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 21 | 0.040 |
Why?
| | Pneumothorax | 1 | 2021 | 38 | 0.040 |
Why?
| | Thyroid Diseases | 1 | 2000 | 35 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 140 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 337 | 0.040 |
Why?
| | Radiotherapy | 1 | 2021 | 185 | 0.040 |
Why?
| | Molecular Weight | 2 | 1989 | 330 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1327 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 379 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1686 | 0.040 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 17 | 0.040 |
Why?
| | Skull Neoplasms | 1 | 1998 | 22 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1033 | 0.040 |
Why?
| | Vincristine | 2 | 2010 | 108 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1281 | 0.040 |
Why?
| | Fluorouracil | 2 | 2010 | 197 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 73 | 0.030 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 26 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2017 | 53 | 0.030 |
Why?
| | Polymyositis | 1 | 1996 | 15 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 956 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 50 | 0.030 |
Why?
| | Neutropenia | 1 | 1995 | 137 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2510 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 139 | 0.030 |
Why?
| | Time Factors | 3 | 2018 | 6545 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 186 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 1996 | 240 | 0.030 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1994 | 21 | 0.030 |
Why?
| | Fever | 1 | 1995 | 298 | 0.030 |
Why?
| | Middle Aged | 7 | 2017 | 31165 | 0.030 |
Why?
| | Klinefelter Syndrome | 1 | 1995 | 56 | 0.030 |
Why?
| | Laparotomy | 1 | 1994 | 106 | 0.030 |
Why?
| | Aged | 4 | 2022 | 22101 | 0.030 |
Why?
| | Health Status | 1 | 1999 | 758 | 0.030 |
Why?
| | Emergencies | 1 | 1994 | 156 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2008 | 1160 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3084 | 0.030 |
Why?
| | Program Development | 1 | 2015 | 355 | 0.030 |
Why?
| | Transcription Factors | 1 | 2021 | 1645 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2013 | 1690 | 0.030 |
Why?
| | Physical Examination | 1 | 1994 | 234 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1723 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 1988 | 0.020 |
Why?
| | Appendicitis | 1 | 1994 | 125 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 1994 | 199 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2271 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1290 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2563 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 307 | 0.020 |
Why?
| | United States | 3 | 2017 | 13906 | 0.020 |
Why?
| | Radiography | 1 | 1994 | 797 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 588 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 877 | 0.020 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2010 | 33 | 0.020 |
Why?
| | Hyperuricemia | 1 | 2010 | 44 | 0.020 |
Why?
| | Hyperkalemia | 1 | 2010 | 24 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2010 | 112 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 232 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1271 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2007 | 193 | 0.020 |
Why?
| | Herpesvirus 4, Human | 2 | 1998 | 157 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1995 | 1708 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 313 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 86 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 73 | 0.020 |
Why?
| | Urogenital Neoplasms | 1 | 2006 | 5 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2006 | 92 | 0.020 |
Why?
| | Behavior | 1 | 2006 | 92 | 0.020 |
Why?
| | Thrombosis | 1 | 1989 | 349 | 0.020 |
Why?
| | Rituximab | 1 | 2006 | 164 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2010 | 614 | 0.020 |
Why?
| | Hemorrhage | 1 | 2010 | 679 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4405 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2006 | 377 | 0.010 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 72 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 7064 | 0.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2010 | 576 | 0.010 |
Why?
| | RNA, Viral | 2 | 1998 | 620 | 0.010 |
Why?
| | Survival | 1 | 2003 | 38 | 0.010 |
Why?
| | Stereotaxic Techniques | 1 | 2003 | 37 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 2003 | 72 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2003 | 213 | 0.010 |
Why?
| | Morbidity | 1 | 2003 | 302 | 0.010 |
Why?
| | Immunotherapy | 1 | 2006 | 596 | 0.010 |
Why?
| | Motor Activity | 1 | 2006 | 684 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2006 | 816 | 0.010 |
Why?
| | Hyperthyroidism | 1 | 2000 | 28 | 0.010 |
Why?
| | Sleep | 1 | 2006 | 688 | 0.010 |
Why?
| | Hypothyroidism | 1 | 2000 | 70 | 0.010 |
Why?
| | Thyroid Nodule | 1 | 2000 | 56 | 0.010 |
Why?
| | Sella Turcica | 1 | 1998 | 16 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 46 | 0.010 |
Why?
| | Health Status Indicators | 1 | 1999 | 166 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 64 | 0.010 |
Why?
| | Fatal Outcome | 1 | 1998 | 299 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 141 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1997 | 296 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1997 | 425 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 2000 | 311 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 228 | 0.010 |
Why?
| | Prednisone | 1 | 1996 | 234 | 0.010 |
Why?
| | Pineal Gland | 1 | 1995 | 16 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1995 | 326 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 2 | 1998 | 3394 | 0.010 |
Why?
| | Anesthesia, Dental | 1 | 1974 | 20 | 0.010 |
Why?
| | Tooth Extraction | 1 | 1974 | 23 | 0.010 |
Why?
| | Anesthesia, General | 1 | 1974 | 54 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 1996 | 482 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1996 | 1433 | 0.010 |
Why?
| | Quality of Life | 1 | 2003 | 2694 | 0.010 |
Why?
| | Cohort Studies | 1 | 2000 | 5434 | 0.010 |
Why?
| | Neutrophils | 1 | 1995 | 1209 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2003 | 10221 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 5427 | 0.000 |
Why?
| | Prospective Studies | 1 | 1995 | 7145 | 0.000 |
Why?
| | Risk Factors | 1 | 1995 | 9787 | 0.000 |
Why?
| | Oral Hemorrhage | 1 | 1974 | 3 | 0.000 |
Why?
| | Tachycardia | 1 | 1974 | 57 | 0.000 |
Why?
| | Angina Pectoris | 1 | 1974 | 67 | 0.000 |
Why?
| | Postoperative Care | 1 | 1974 | 239 | 0.000 |
Why?
| | Arrhythmias, Cardiac | 1 | 1974 | 321 | 0.000 |
Why?
| | Anticoagulants | 1 | 1974 | 637 | 0.000 |
Why?
|
|
Greffe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|